Aroa Biosurgery Limited

CHIA:ARX Stock Report

Market Cap: AU$257.0m

Aroa Biosurgery Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Brian Ward

Chief executive officer

NZ$1.1m

Total compensation

CEO salary percentage54.1%
CEO tenure17.3yrs
CEO ownership9.6%
Management average tenure3.8yrs
Board average tenure9.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Brian Ward's remuneration changed compared to Aroa Biosurgery's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-NZ$8m

Jun 30 2024n/an/a

-NZ$9m

Mar 31 2024NZ$1mNZ$583k

-NZ$11m

Dec 31 2023n/an/a

-NZ$9m

Sep 30 2023n/an/a

-NZ$8m

Jun 30 2023n/an/a

-NZ$4m

Mar 31 2023NZ$1mNZ$552k

-NZ$396k

Dec 31 2022n/an/a

-NZ$1m

Sep 30 2022n/an/a

-NZ$2m

Jun 30 2022n/an/a

-NZ$5m

Mar 31 2022NZ$1mNZ$542k

-NZ$8m

Dec 31 2021n/an/a

-NZ$10m

Sep 30 2021n/an/a

-NZ$11m

Jun 30 2021n/an/a

-NZ$15m

Mar 31 2021NZ$2mNZ$483k

-NZ$19m

Compensation vs Market: Brian's total compensation ($USD605.22K) is about average for companies of similar size in the Australian market ($USD675.93K).

Compensation vs Earnings: Brian's compensation has been consistent with company performance over the past year.

CEO

Brian Ward

17.3yrs

Tenure

NZ$1,078,619

Compensation

Dr. Brian Ward, B.V.Sc, MBA(dist) has been Executive Director at Aroa Biosurgery Limited since September 21, 2007 and serves as its Managing Director and Chief Executive Officer. He has founded Aroa Biosur...

Leadership Team

NamePositionTenureCompensationOwnership
Brian Ward
Founderno dataNZ$1.08m9.6%
A$ 24.7m
James Agnew
CFO & Joint Company Secretary4.9yrsNZ$627.01kno data
Rod Stanley
Chief Technology Officerless than a yearno datano data
Barnaby May
Chief Scientific Officer3.1yrsno data0.95%
A$ 2.4m
Neetha Alex-Kumar
General Counselno datano datano data
Frazer Murray
Director of Global Marketing & Strategyno datano datano data
Yasmin Winchester
Vice President of Qualityno datano datano data
Tracy Weimar
Joint Company Secretary4.5yrsno datano data
Adam Young
Vice President of Medical Affairsno datano datano data

3.8yrs

Average Tenure

Experienced Management: ARX's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Brian Ward
Founder17.3yrsNZ$1.08m9.6%
A$ 24.7m
James McLean
Independent Non-Executive Chairperson13.4yrsNZ$212.19k0.82%
A$ 2.1m
John Diddams
Independent Non-Executive Director5.2yrsNZ$159.36k0.35%
A$ 888.5k
John Pinion
Independent Non-Executive Director9.9yrsNZ$187.52k0.14%
A$ 352.0k
Philip McCaw
Non-Executive Director16.8yrsNZ$130.68k5.68%
A$ 14.6m
Catherine Mohr
Independent Non-Executive Director2.2yrsNZ$178.02k0.13%
A$ 325.1k
Darla Hutton
Independent Non-Executive Directorless than a yearNZ$4.73k0.041%
A$ 104.4k

9.9yrs

Average Tenure

58yo

Average Age

Experienced Board: ARX's board of directors are considered experienced (9.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 05:05
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aroa Biosurgery Limited is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Russell WrightBarclay Pearce Capital Pty Limited
John HesterBell Potter
Elyse ShapiroBell Potter